What were the key takeaways from BioCryst Pharmaceuticals's earnings call?

What is BioCryst Pharmaceuticals's gross profit margin?

What factors drove the changes in BioCryst Pharmaceuticals's revenue and profit?

Did BioCryst Pharmaceuticals beat or miss consensus estimates last quarter?

What is the market's earnings forecast for BioCryst Pharmaceuticals next quarter?

What is the revenue and EPS growth rate for BioCryst Pharmaceuticals year over year?

What does BioCryst Pharmaceuticals do and what are its main business segments?

What guidance did BioCryst Pharmaceuticals's management provide for the next earnings period?

- **Revenue Growth**: ORLADEYO up 43% YoY, driving $214M operating profit. 
- **HAE Portfolio Expansion**: Launches ORLADEYO pellets for kids, Navenibart Phase II shows 92% attack reduction. 
- **2026 Outlook**: $625-645M revenue, 4x ROI on sales spend, $400M credit facility for M&A flexibility. 
- **Strategic Focus**: Build durable HAE franchise with 3 distinct prophylaxis options; rare disease pipeline expansion.

**【CEO Summary Section】**
- **2025 Revenue Growth**: ORLADEYO revenue reached $601.8 million, up 38% year-over-year, with 43% growth excluding Europe. 
- **HAE Portfolio Expansion**: Acquired Astra Therapeutics to strengthen HAE portfolio with ORLADEYO (capsules, pellets) and Navenibart. 
- **Super Responder Strategy**: 60% of patients stay on ORLADEYO long-term, driven by 91% attack reduction; pediatric pellets launched to address underdiagnosed cases. 
- **Navenibart Potential**: Phase II data shows 92% attack reduction, positioning as a 2-4x/year injectable alternative to current 100+ injections/year regimens. 
- **Rare Disease Pipeline**: BCX17725 for Netherton syndrome in Phase I, targeting 2026 patient data release. 

**【CFO Financial Commentary】**
- **2025 Financial Highlights**: Non-GAAP ORLADEYO revenue +43%, operating profit $214M (+198%), R&D costs down 10%. 
- **2026 Guidance**: Revenue $625-645M (+13%), OpEx $450-470M. 
- **Liquidity**: $337.5M cash, $400M Blackstone credit facility. 
- **ROI Efficiency**: Sales & marketing spend generates 4x return on ORLADEYO net sales. 

**【Q&A Key Highlights】**
- **Navenibart Timeline**: BLA submission by end-2027, targeting 2028 approval. Phase III enrollment on track for mid-2026 completion. 
- **Market Positioning**: ORLADEYO for oral-first patients; Navenibart for injectable loyalists seeking reduced dosing frequency. 
- **Pediatric Launch**: 2026 guidance includes minimal contribution, but long-term potential to double diagnosed pediatric cases. 
- **Competitive Impact**: No material impact from new entrants; focus on net patient growth (~150/year to reach $1B by 2029). 
- **Financial Split**: >90% of 2026 revenue from U.S., with Europe excluded from core metrics.

BioCryst Pharmaceuticals, Inc. (BCRX) Q4 2025 Earnings Call Transcript

- **Revenue Surge**: ORLADEYO up 37% YoY to $159.1M, with U.S. sales dominating at 89%. Full-year guidance raised to $590-600M. 
- **Strategic Wins**: European sale & debt repayment; $400M Astria acquisition for navenibart. 
- **Pipeline Momentum**: BCX17725 skin penetration in healthy volunteers; DME program to be spun/partnered. 
- **Financial Strength**: $269M cash pre-close; 2025 non-GAAP net income positive. 
- **Pediatric Play**: 500 diagnosed pediatric HAE patients; PDUFA mid-Dec with payer alignment intact.

**【CEO Summary Section】**
- **ORLADEYO Revenue Growth**: Q3 revenue of $159.1M, up 37% YoY, driven by U.S. sales ($141.6M, 89% of total). Full-year guidance raised to $590-600M, with $1B peak by 2029. 
- **Strategic Transactions**: Sold European business, repaid $200M Pharmakon debt, and announced Astria acquisition (navenibart) for $400M in Q1 2026. 
- **Pipeline Progress**: BCX17725 (Netherton) shows skin penetration in healthy volunteers; DME program to be spun/partnered post-Q1 data. 
- **Leadership Transition**: Charlie Gayer to CEO, Ron Dullinger to lead U.S. commercial team.

**【CFO Financial Commentary】**
- **Financial Highlights**: Non-GAAP net income $35.6M (EPS $0.17), up 107% YoY. Cash $269M (pre-close of European sale). 
- **Cost Efficiency**: Operating expenses $118M (up 28% YoY), with R&D investment. 2025 guidance: $430-440M OpEx, positive cash flow. 
- **Liquidity**: $294M post-European sale; targeting $1B cash by 2029. 

**【Q&A Key Highlights】**
- **ORLADEYO Competition**: Retention rate stable at 60%, with 64 new prescribers Q3. Gross-to-net ~15%, stable through 2026. 
- **Pediatric Launch**: 500 diagnosed pediatric HAE patients, 40% untreated. PDUFA date mid-Dec; payer alignment similar to adult. 
- **DME Program**: Decision to de-prioritize due to cost and expertise; Phase I data pending. 
- **Netherton Progress**: BCX17725 shows skin penetration; Q1 2026 data from 10+ patients. SubQ/IV dosing exploration ongoing. 
- **Regulatory Updates**: FDA interactions stable despite shutdown; no PDUFA delay anticipated.

BioCryst Pharmaceuticals, Inc. (BCRX) Q3 2025 Earnings Call Transcript

- **Record Q2 Growth**: ORLADEYO revenue up 45% YoY to $156.8 million, driven by 15% new patient growth Q/Q.
- **European Business Sale**: $20-25M annual revenue to be reinvested, enabling $700M+ cash by 2027.
- **Pipeline Momentum**: Netherton and DME programs on track for late 2025 data readouts.
- **Financial Strength**: $32.3M non-GAAP net income, 60% patient retention rate, and no material MFN policy impact.

**【CEO Summary Section】**
- ORLADEYO achieved record Q2 revenue of $156.8 million, up 45% YoY, driven by new patient demand and improved execution. 
- Signed definitive agreement to sell European business, enabling debt repayment and enhanced cash flow generation.
- Announced CEO transition to Charlie Gayer, positioning BioCryst for growth as a rare disease consolidator.

**【President (Charlie Gayer) Commercial Update】**
- Q2 new patient prescriptions up 15% vs Q1 2025 and 10% vs Q2 2021, with 69 new prescribers.
- 60% 1-year retention rate remains stable, with 90% of U.S. revenue from ORLADEYO.
- Netherton syndrome and DME pipeline programs on track for late 2025 data readouts.

**【CFO (Babar Ghias) Financial Commentary】**
- Total Q2 revenue $163.4 million, with $140.3 million from U.S. ORLADEYO.
- Non-GAAP net income $32.3 million ($0.15 EPS), up from $21.7 million ($0.10 EPS) in Q2 2024.
- Generated $45 million cash flow, with $125 million debt repayment to date.
- Projected $700 million cash by 2027, positioning for strategic acquisitions.

**【Q&A Highlights】**
- Discontinuation rate stable at 60% YoY, driven by real-world evidence showing 75% attack rate reduction.
- European business sale expected to close in early October, removing $20-25 million Q4 2025 revenue.
- Netherton syndrome Phase 1b data expected to show skin penetration and efficacy signals.
- DME Phase 1 data to assess single-dose efficacy in reducing retinal swelling.
- No impact from new competitors; ORLADEYO's oral convenience maintains 50%+ market share.

BioCryst Pharmaceuticals, Inc. (BCRX) Q2 2025 Earnings Call Transcript

- **Revenue Supercharge**: ORLADEYO Q1 revenue up 33% YoY to $134M, with paid rate jumping 10pts to 84%.
- **Pipeline Momentum**: Pediatric ORLADEYO NDA filed; BCX17725 Phase 1 for Netherton syndrome and avoralstat for DME trials underway.
- **Financial Strength**: Full-year profitability expected in 2025; $75M debt repayment slashes interest costs by $23M.
- **Growth Catalysts**: Medicare IRA driving 2/3 of paid rate improvement; 70% HAE patients now prefer oral prophylaxis.


**【CEO Opening Remarks】**
- Q1 2025 revenue of $134M for ORLADEYO, driven by a 10% increase in U.S. paid patient rate to 84%.
- Annual revenue guidance raised to $580-600M (33-37% YoY growth), with full-year profitability expected in 2025.
- $75M debt repayment in April, reducing outstanding debt to $249M and saving $23M in interest over the debt term.

**【Charlie Gayer - ORLADEYO Commercial Update】**
- U.S. paid rate jumped 10pts QoQ, exceeding expectations due to Medicare Inflation Reduction Act (IRA) and improved commercial conversion.
- 70% of U.S. HAE patients now prefer oral prophylaxis, up from 51% in 2023, with 84% of patients on therapy now paying.
- Q2 revenue growth expected to be $10-12M, less pronounced than prior years due to earlier revenue capture in Q1.

**【Helen Thackray - Pipeline Progress】**
- Pediatric ORLADEYO granule NDA submitted to FDA for 2-11 year olds, with filings in Europe, Japan, and Canada.
- BCX17725 Phase 1 trial for Netherton syndrome initiated in U.S. and Australia, targeting KLK5 inhibition to restore skin barrier function.
- Avalorstat Phase 1 trial for diabetic macular edema (DME) expected to report initial data by end-2025, focusing on retinal thickness reduction.

**【Jon Stonehouse - Financial Review】**
- Total Q1 revenue $145.5M, with $134.2M from ORLADEYO (89.5% U.S.).
- Operating expenses $102.9M, up 10% YoY due to commercial growth and international expansion.
- Cash balance $317M, with non-GAAP operating expense guidance raised to $440-450M for 2025.

**【Q&A Highlights】**
- Pediatric HAE market: ~500 patients in U.S., 200+ eligible for prophylaxis; oral granules expected to dominate injectable competition.
- DME trial: seeking >10% reduction in retinal thickness as signal of efficacy, with 12-week dosing planned based on initial results.
- Netherton syndrome: Phase 1 trial targeting skin healing and itch reduction, with potential dose escalation if needed.


BioCryst Pharmaceuticals (BCRX)-5 May 25-2025 Q1 Earnings call transcript

- **Record 2024 Performance**: ORLADEYO revenue up 34% YoY, with 2024 operating profit of $62.9M vs. 2023 loss of $48.1M.
- **Pipeline Momentum**: BCX17725 Phase I trials underway for Netherton syndrome; avoralstat DME trials to begin in 2025.
- **Expanded Guidance**: 2025 ORLADEYO revenue raised to $535–$550M, driven by Medicare patient affordability.
- **Pediatric Potential**: ORLADEYO pediatric granule trial shows 97% retention; NDA submission on track for late 2025.
- **Cash Flow Growth**: $600M+ cash by 2027, enabling debt reduction and capital markets independence.

**【CEO Summary Section】**
- BioCryst achieved record performance in 2024, with ORLADEYO revenue growing 34% year-over-year and adding as many patients as the first year of launch.
- Advanced pipeline programs include BCX17725 for Netherton syndrome entering clinical trials and avoralstat for diabetic macular edema (DME) set to begin trials in 2025.
- The company generated a non-GAAP operating profit of $62.9 million in 2024, up from a loss of $48.1 million in 2023, with free cash flow expected to exceed $600 million by 2027.

**【CFO Financial Commentary】**
- Q4 2024 total revenue was $131.5 million, with ORLADEYO contributing $124.2 million (94% of total revenue).
- Full-year 2024 revenue reached $450.7 million, with ORLADEYO accounting for $437.7 million (97% of total revenue).
- Operating expenses (excluding stock-based compensation) increased by just $8 million year-over-year, despite revenue growth of $119 million.
- 2025 ORLADEYO revenue guidance raised to $535–$550 million, driven by Medicare patient affordability under the Inflation Reduction Act.

**【Commercial Highlights】**
- ORLADEYO pediatric granule formulation demonstrated 97% patient retention in the APeX-P trial, with 25/29 patients remaining on therapy.
- 97% of U.S. HAE treaters surveyed are considering prescribing ORLADEYO, with 59% extremely likely to prescribe to more patients in 2025.
- Medicare patient paid rate for ORLADEYO is expected to rise from 55% in Q4 2024 to potentially 80% by year-end 2025.

**【Pipeline Progress】**
- BCX17725 for Netherton syndrome: Phase I trial in healthy volunteers and patients underway, with initial data expected late 2025.
- Avoralstat for DME: Preclinical data shows inhibition of retinal vascular leakage; first-in-human trials set to begin in 2025.
- ORLADEYO pediatric NDA submission on track for late 2025, targeting 500+ U.S. children under age 12 with HAE.

**【Financial Outlook】**
- 2025 total revenue guidance raised to $560–$575 million, driven by ORLADEYO growth and international demand.
- Operating expenses (excluding stock-based compensation) expected to remain within $425–$435 million range.
- Positive quarterly cash flow anticipated in 2025, with annual cash flow generation starting in 2026.


Actual												-0.24	-0.24	-0.26	-0.34	-0.36	-0.24	-0.33	-0.1	-0.4	-0.32	-0.23	-0.38	-0.28	-0.4	-0.19	-0.31	-0.17	-0.06	-0.07	-0.13	0	0.02	0.06	1.12
Forecast												-0.2422	-0.2556	-0.255	-0.251	-0.267	-0.2336	-0.2927	-0.295	-0.3625	-0.3436	-0.2855	-0.1664	-0.2987	-0.234	-0.245	-0.2459	-0.2093	-0.173	-0.068	-0.0509	-0.0748	0.007	0.0398	0.0483
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	+0.91%	+6.10%	-1.96%	-35.46%	-34.83%	-2.74%	-12.74%	+66.10%	-10.34%	+6.87%	+19.44%	-128.37%	+6.26%	-70.94%	+22.45%	-26.07%	+18.78%	+65.32%	-2.94%	-155.40%	+100.00%	+185.71%	+50.75%	+2218.84%

BCRX

BCRX fundamentals

BCRX Q4 2025 Earnings

Earnings Call

You can ask Aime

BCRX

BCRX fundamentals

BCRX Q4 2025 Earnings

Earnings Call

BCRX Earnings Call Summary for Q4/20258:30 AM on Feb 26, 2026

BCRX Earnings Call Summary for Q3/20258:30 AM on Nov 3, 2025

BCRX Earnings Call Summary for Q2/20258:30 AM on Aug 4, 2025

BCRX Earnings Call Summary for Q1/20258:30 AM on May 5, 2025

BCRX Earnings Call Summary for Q4/20248:30 AM on Feb 24, 2025

You can ask Aime